Appl. No. 10/583,464 Amdt. dated September 4, 2009 Response to Office Action of August 12, 2009

REMARKS/ARGUMENTS

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants have amended the specification as set forth above, and hereby submit a substitute Sequence Listing in both paper and computer readable form.

The amendments to the specification are made to insert the required SEQ ID NO identifiers in connection with SEQ ID NO:22 (at paragraph 0105), and SEQ ID NO:55 (at paragraphs 0157, 0177, 0178, 0181, and 0182).

The amendments are also made to correct an obvious typographical error in paragraph 0086. The three-letter code for isoleucine incorrectly read "IIe", rather than "IIe".

The amendments are also made to correct an obvious omission of the first position amino acid residue in SEQ ID NOs:15 and 18 in paragraph 0074. The leading D residue in SEQ ID NO:15, and the leading F residue in SEQ ID NO:18 were inadvertently omitted from the sequences set forth in paragraph 0074. The sequence listing filed with the application clearly shows the presence of these leading residues in SEQ ID NOs:15 and 18, and the omitted residues are present in the recitation of SEQ ID NOs:15 and 18 in the "Brief Description of Sequences" between paragraphs 0065 and 0066 of the specification. Further, the recitation of the amino acid positions encompassed by SEQ ID NOs:15 and 18 in paragraph 0074, i.e., "Heat Shock Protein 65: hsp65₁₅₃₋₁₇₄" and Tetanus toxoid: TT₉₄₇₋₉₆₇" are consistent with the omission of a single residue from each sequence. No new matter is added by the present amendment.

In accordance with 37 C.F.R. §1.825(a), Applicants hereby submit substitute sheets of the paper copy of the Sequence Listing. The substitute sheets include SEQ ID NO:55, which appears in the originally filed specification at paragraphs 0157, 0177, 0178, 0181, and 0182. The substitute sheets include no new matter. Please replace the current paper copy of the Sequence Listing with the substitute sheets submitted herewith.

In accordance with 37 C.F.R. §1.825(b), Applicants hereby submit a substitute copy of the computer readable form of the Sequence Listing. The substitute copy of the

Appl. No. 10/583,464 Amdt. dated September 4, 2009 Response to Office Action of August 12, 2009

computer readable form of the Sequence Listing is the same as the substitute copy of the paper Sequence Listing submitted herewith.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Lance A. Termes Reg. No. 43,184

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 650-326-2400

Fax: 415-576-0300 LAT:y1m